CINECA IRIS Institutional Research Information System

FOGLI, STEFANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.756
AS - Asia 4.905
EU - Europa 4.755
SA - Sud America 681
AF - Africa 241
OC - Oceania 36
Continente sconosciuto - Info sul continente non disponibili 3
Totale 21.377
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.419
SG - Singapore 1.657
IT - Italia 1.529
CN - Cina 1.352
DE - Germania 727
HK - Hong Kong 675
SE - Svezia 648
BR - Brasile 558
VN - Vietnam 383
GB - Regno Unito 371
BG - Bulgaria 287
CA - Canada 237
FR - Francia 226
TR - Turchia 198
FI - Finlandia 183
IN - India 176
RU - Federazione Russa 165
AT - Austria 133
JP - Giappone 113
CI - Costa d'Avorio 82
PL - Polonia 81
UA - Ucraina 78
MX - Messico 57
BD - Bangladesh 53
KR - Corea 51
GR - Grecia 50
NL - Olanda 50
CH - Svizzera 49
ES - Italia 44
AR - Argentina 40
BE - Belgio 40
SN - Senegal 37
AU - Australia 33
PK - Pakistan 30
ZA - Sudafrica 30
IQ - Iraq 28
IL - Israele 26
MA - Marocco 24
ID - Indonesia 23
IR - Iran 22
CO - Colombia 20
NG - Nigeria 20
RO - Romania 20
SA - Arabia Saudita 19
VE - Venezuela 19
EC - Ecuador 17
PT - Portogallo 12
EG - Egitto 11
RS - Serbia 11
PH - Filippine 10
UZ - Uzbekistan 10
AE - Emirati Arabi Uniti 9
JO - Giordania 9
KE - Kenya 9
TW - Taiwan 9
JM - Giamaica 8
MY - Malesia 8
NP - Nepal 8
UY - Uruguay 8
AL - Albania 6
CR - Costa Rica 6
CZ - Repubblica Ceca 6
HU - Ungheria 6
LT - Lituania 6
PE - Perù 6
AZ - Azerbaigian 5
CL - Cile 5
DO - Repubblica Dominicana 5
ET - Etiopia 5
LB - Libano 5
PY - Paraguay 5
TN - Tunisia 5
TT - Trinidad e Tobago 5
BY - Bielorussia 4
IE - Irlanda 4
PA - Panama 4
SV - El Salvador 4
AO - Angola 3
BJ - Benin 3
BO - Bolivia 3
CY - Cipro 3
DK - Danimarca 3
DM - Dominica 3
KG - Kirghizistan 3
KZ - Kazakistan 3
NO - Norvegia 3
PS - Palestinian Territory 3
SI - Slovenia 3
TH - Thailandia 3
A1 - Anonimo 2
AM - Armenia 2
BB - Barbados 2
BH - Bahrain 2
DZ - Algeria 2
GD - Grenada 2
GH - Ghana 2
MK - Macedonia 2
NZ - Nuova Zelanda 2
OM - Oman 2
BA - Bosnia-Erzegovina 1
Totale 21.351
Salva come PNG Salva come JPEG
Città #
Ashburn 1.082
Woodbridge 1.048
Singapore 850
Fairfield 702
Hong Kong 659
Santa Clara 641
Chandler 605
Ann Arbor 604
Houston 566
Dallas 528
San Jose 477
Serra 307
Shanghai 300
Sofia 284
Seattle 281
Beijing 267
Wilmington 265
Milan 229
New York 225
Cambridge 214
Los Angeles 174
Boardman 160
Ottawa 157
Princeton 144
Pisa 128
Lawrence 119
Vienna 118
London 109
Izmir 105
Medford 105
Lauterbourg 101
Ho Chi Minh City 97
Council Bluffs 95
Jacksonville 95
Tokyo 94
Florence 90
Nanjing 86
Munich 84
Abidjan 82
Hefei 81
Frankfurt am Main 78
Rome 74
Warsaw 68
Dearborn 67
Hanoi 65
Des Moines 61
São Paulo 57
Dong Ket 54
Redwood City 54
Redondo Beach 53
Helsinki 49
Buffalo 48
Istanbul 47
Ogden 45
Seoul 44
Lancaster 40
Dakar 37
Turku 36
Marseille 35
Nanchang 34
San Diego 34
Bern 33
Columbus 31
The Dalles 29
Brussels 27
Orem 27
Phoenix 27
Falls Church 25
Jüchen 25
Pune 24
Toronto 24
Chennai 23
Bremen 22
Brooklyn 22
Kunming 22
Montreal 22
San Francisco 22
Tianjin 22
Chicago 21
Fuzhou 21
Atlanta 20
Changsha 20
Guangzhou 20
Lagos 20
Nürnberg 20
Belo Horizonte 18
Rio de Janeiro 18
Mumbai 17
Brasília 15
Cascina 15
Johannesburg 15
Norwalk 15
Shenyang 15
Stockholm 15
Lucca 14
Naples 14
Pistoia 14
Venice 14
Wuhan 14
Zurich 14
Totale 14.234
Salva come PNG Salva come JPEG
Nome #
Cytotoxic Activity of Oleocanthal Isolated from Virgin Olive Oil on Human Melanoma Cells 374
The molecular bases of cannabinoid action in cancer 343
Corticosteroids in oncology: Use, overuse, indications, contraindications. An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper 334
AM251 induces apoptosis and G2/M cell cycle arrest in A375 human melanoma cells 330
Synthesis of Novel 3,5-Disubstituted-2-oxindole Derivatives As Antitumor Agents against Human Nonsmall Cell Lung Cancer 294
Anticancer activity of euplotin C, isolated from the marine ciliate euplotes crassus, against human melanoma cells 285
Circulating MicroRNAs in Cutaneous Melanoma Diagnosis and Prognosis 259
Oleocanthal and oleacein contribute to the in vitro therapeutic potential of extra virgin oil-derived extracts in non-melanoma skin cancer 256
Cholinesterase-like organocatalysis by imidazole and imidazole-bearing molecules 248
Sucrosomial iron and traditional iron dosage forms are compared for absorption by Caco2 cells. 240
Cannabinoid derivatives induce cell death in pancreatic MIA PaCa-2 cells via a receptor-independent mechanism 236
Variable correlation between 6-mercaptopurine metabolites in erythrocytes and hematologic toxicity: implications for drug monitoring in children with acute lymphoblastic leukemia 235
A flexible SNP genotyping system to study allelic determinants of brain function. 234
New quinolone- and 1,8-naphthyridine-3-carboxamides as selective CB2 receptor agonists with anticancer and immuno-modulatory activity 232
Protective effect of high-dose montelukast on salbutamol-induced homologous desensitisation in airway smooth muscle. 224
Survivin-directed molecular beacon as potential theranostic agent in melanoma cells 224
Analysis of the Antitumor Activity of Clotrimazole on A375 Human Melanoma Cells 223
Anti-proliferative activity of oleocanthal in human malignant cutaneous melanoma cells 221
Comparison of digital PCR systems for the analysis of liquid biopsy samples of patients affected by lung and colorectal cancer 220
Selection of a human butyrylcholinesterase-like antibody single-chain variable fragment resistant to AChE inhibitors from a phage library expressed in E. coli. 214
Sucrosomial® iron absorption studied by in vitro and ex-vivo models 209
Diclofenac-Derived Hybrids for Treatment of Actinic Keratosis and Squamous Cell Carcinoma 208
Rosiglitazone reverses salbutamol-induced ß(2) -adrenoceptor tolerance in airway smooth muscle. 207
Survivin mRNA detection and silencing by a Molecular Beacon Oligodeoxynucleotide in living cutaneous melanoma cells 203
Anticancer activity of anandamide in human cutaneous melanoma cells 203
Detection and silencing of survivin mRNA by bi-color imaging based on PMMA nanoparticles/molecular beacon in human cancer cells 202
Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients 200
Role of miR-34a as biomarker and therapeutic agent in cutaneous melanoma 196
Identification of plasma microRNAs as new potential biomarkers with high diagnostic power in human cutaneous melanoma. 195
The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer 194
Chronic administration of suramin induces neurotoxicity in rats 192
Survivin directed molecular beacon as potential “theranostic agent” in melanoma cells 192
Lung tissue penetration and plasma pharmacokinetics of azithromycin after multiple oral doses of 500 and 1000 mg in adults 191
Tumor-promoting effects of cannabinoid receptor type 1 in human melanoma cells. 190
Evaluation of circulating microRNAs as diagnostic circulating biomarkers in cutaneous melanoma 190
Identification of five circulating microRNAs with high diagnostic values in cutaneous melanoma 187
Clinical utility of Next Generation Sequencing of plasma cell-free DNA for the molecular profiling of patients with NSCLC at diagnosis and disease progression 184
An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma. 184
Matrix metalloproteinase inhibitors prevent the release and proteolytic activity of monocyte/macrophage-derived microparticles 183
Synergistic interaction between PPAR ligands and salbutamol on human bronchial smooth muscle cell proliferation. 181
Cytotoxic effects of Echinacea root hexanic extracts on human cancer cell lines 181
Potential relationship between the expression of Cx26/Cx43 and the BRAF mutation status in human melanoma cells 179
Synthesis and in-vitro antitumour activity of new naphthyridine derivatives on human pancreatic cancer cells 179
Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy 179
Diagnosis and treatment monitoring in breast cancer: how liquid biopsy can support patient management 179
Cannabinoid derivatives induce cell death in MIA Paca-2 cell line via a receptor-indipendent mechanism 177
Clinical pharmacology of intravitreal anti-VEGF drugs 177
Montelukast prevents microparticle-induced inflammatory and functional alterations in human bronchial smooth muscle cells. 177
Application of a pharmacokinetic/pharmacogenetic approach to assess the nicotine metabolic profile of smokers in the real-life setting 176
Antiproliferative effects of Echinacea root hexanic extracts on Mia Paca-2 cells 174
Genotype-based therapeutic approach for colorectal cancer: state of the art and future perspectives 172
Theranostic properties of a survivin-directed molecular beacon in human melanoma cells 172
Pharmacogenetic determinants of anti-cancer drug activity and toxicity 169
Implications of KRAS mutations in acquired resistance to treatment in NSCLC 167
Circulating microRNAs as biomarkers for early diagnosis of cutaneous melanoma 165
Montelukast reverses albuterol-induced b2-adrenoceptor tolerance in airway smooth muscle 163
A flexible SNP genotyping system to study allelic determinants of brain function 162
Ceramide analogues in apoptosis: a new strategy for anticancer drug development 160
Therapeutic potential of sulindac hydroxamic acid against human pancreatic and colonic cancer cells 159
Gemcitabine plus nab-paclitaxel induces PD-L1 mRNA expression in plasma-derived microvesicles in pancreatic cancer 159
Pathophysiology and pharmacological targets of VEGF in diabetic macular edema 158
Design, synthesis and pro-apoptotic antitumour properties of indole-based 3,5-disubstituted oxadiazoles 157
Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer 157
Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer 157
Inhibitory effect of suramin in rat models of angiogenesis in vitro and in vivo 157
EGFR-TKIs in non-small-cell lung cancer: Focus on clinical pharmacology and mechanisms of resistance 156
Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs 155
Pharmacogenetic foundations of therapeutic efficacy and adverse events of statins 155
In vitro investigation of sulindac derivatives as potential anticancer agents 152
Synthesis and evaluation of indole-containing 3,5-diarylisoxazoles as potential pro-apoptotic antitumour agents. 151
Conformationally restrained ceramide analogues: effects of lipophilic modifications on the antiproliferative activity 151
Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naïve patients with advanced non-small-cell lung cancer 151
Synthesis, characterization and evaluation of thiolated quaternary ammonium-chitosan conjugates for enhanced intestinal drug permeation 148
Design, synthesis, and characterization of the antitumor activity of novel ceramide analogues 148
High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study 145
Endothelial nitric oxide synthase c.-813C>T predicts for proteinuria in metastatic breast cancer patients treated with bevacizumab-based chemotherapy 145
In vivo adenosine A(2B) receptor desensitization in guinea-pig airway smooth muscle: Implications for asthma 144
Manumycin inhibits ras signal transduction pathway and induces apoptosis in COLO320-DM human colon tumour cells 141
The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide 138
Synthesis, characterization and evaluation of thiolated quaternary ammonium-chitosan conjugates for enhanced intestinal drug permeation 137
Influence of polysaccharides on expression of membrane-associated muc1 in cultivated epithelial cells 136
Clinical pharmacology and drug-drug interactions of lenvatinib in thyroid cancer 136
Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients 135
Attività antiproliferativa dell’oleocantale in cellule umane di melanoma cutaneo maligno. 134
Blood-based PD-L1 analysis in tumor-derived extracellular vesicles: Applications for optimal use of anti-PD-1/PD-L1 axis inhibitors 132
Farmacogenetica nelle neoplasie gastriche 131
Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib 131
Metabolism of 6-mercaptopurine in the erythrocytes, liver, and kidney of rats during multiple-dose regimens 129
Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients 129
Pharmacological insights on novel oral selective estrogen receptor degraders in breast cancer 128
New chitosan derivatives for the preparation of rokitamycin loaded microspheres designed for ocular or nasal administration 128
Abemaciclib pharmacology and interactions in the treatment of HR+/HER2− breast cancer: a critical review 127
Erratum: Clinical pharmacology of monoclonal antibodies targeting PD-1 axis in urothelial cancers 127
The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage 126
Nicotine Metabolite Ratio in Smokers: A Real World Experience 125
Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors 124
Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study 123
ErbB in NSCLC as a molecular target: Current evidences and future directions 122
Characteristics of smokers according to their Nicotine Metabolite Ratio, preliminary results from a real-life experience 122
Cross-Linked Hyaluronic Acid as Tear Film Substitute 121
Totale 18.112
Salva come PNG Salva come JPEG
Categoria #
all - tutte 65.468
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 65.468
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.479 43 77 65 90 233 212 60 70 63 49 86 431
2022/20232.062 257 292 162 169 194 278 37 152 371 10 126 14
2023/20241.411 142 163 158 83 176 252 71 52 29 51 107 127
2024/20254.463 49 173 47 245 506 530 294 200 479 525 456 959
2025/20264.974 342 514 550 465 586 393 787 227 283 405 208 214
2026/2027280 280 0 0 0 0 0 0 0 0 0 0 0
Totale 21.785